ORPHA:36899
Myoclonus-dystonia syndrome
Also known as: Alcohol-responsive dystonia · Hereditary essential myoclonus · Myoclonic dystonia
Publications
1,318
92.7th percentile
Trials
0
Interventional, condition-specific
Researchers
1,302
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
Myoclonus-dystonia syndrome (MDS) is a rare movement disorder characterized by mild to moderate dystonia along with 'lightning-like' myoclonic jerks.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
Additional Mondo synonyms (5)
DYT-SGCE · dystonia with myoclonus · hereditary essential myoclonus · myoclonic dystonia · myoclonus-dystonia syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,318 matched papers (843 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,318
1,318 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,318 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
843 in the last 10 years · high confidence · 92.7th percentile (publications denominator)
Phrase hits: 1,318 · MeSH hits: 0
Who's working on it?
1,302
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Roze E10 papers · 2026
Département de Neurologie, Hôpital Pitié-Salpêtrière, Paris, France.
Papers in Europe PMC - 02Tijssen MAJ9 papers · 2025
Expertise Center Movement Disorders Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands.
Papers in Europe PMC - 03Vidailhet M7 papers · 2026
Sorbonne Université, Paris, France; Inserm U1127, CNRS UMR 7225, UM 75, ICM, Paris, France.
Papers in Europe PMC - 04Zech M7 papers · 2026
Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany. michael.zech@helmholtz-muenchen.de.
Papers in Europe PMC - 05Tarrano C6 papers · 2026
Sorbonne Université, Paris, France; Inserm U1127, CNRS UMR 7225, UM 75, ICM, Paris, France.
Papers in Europe PMC - 06Tranchant C6 papers · 2026
Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Papers in Europe PMC - 07Worbe Y6 papers · 2026
Sorbonne Université, Paris, France; Inserm U1127, CNRS UMR 7225, UM 75, ICM, Paris, France.
Papers in Europe PMC - 08Brochard V5 papers · 2026
Centre d'Investigation Clinique 1422, INSERM/APHP, Paris, France.
Papers in Europe PMC - 09Delorme C5 papers · 2026
Sorbonne Université, Paris, France; Inserm U1127, CNRS UMR 7225, UM 75, ICM, Paris, France.
Papers in Europe PMC - 10Jech R5 papers · 2026
Department of Neurology, 1st Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic. jech@cesnet.cz.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Myoclonus-dystonia syndrome" OR "Alcohol-responsive dystonia" OR "Hereditary essential myoclonus" OR "Myoclonic dystonia" OR "DYT-SGCE" OR "dystonia with myoclonus"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Myoclonus-dystonia syndrome" OR "Alcohol-responsive dystonia" OR "Hereditary essential myoclonus" OR "Myoclonic dystonia" OR "DYT-SGCE" OR "dystonia with myoclonus"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T23:55:19.350Z